Barings’s Haemonetics HAE Stock Holding History

Barings’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-13,605	Closed	-$394K	–	844
2016 Q2	$394K	Hold	13,605	–	–	0.01%	702
2016 Q1	$476K	Sell	13,605 -43,100	-76%	-$1.39M	0.01%	693
2015 Q4	$1.83M	Sell	56,705 -4,395	-7%	-$143K	0.05%	317
2015 Q3	$1.98M	Buy	+61,100	New	+$2.3M	0.05%	297
2015 Q2	–	Sell	-74,303	Closed	-$3.34M	–	992
2015 Q1	$3.34M	Sell	74,303 -47,626	-39%	-$1.99M	0.08%	200
2014 Q4	$4.56M	Sell	121,929 -72,493	-37%	-$2.66M	0.1%	153
2014 Q3	$6.79M	Buy	194,422 +19,122	+11%	+$682K	0.15%	101
2014 Q2	$6.18M	Buy	175,300 +60,267	+52%	+$2.01M	0.19%	113
2014 Q1	$3.75M	Buy	+115,033	New	+$4.4M	0.12%	170

Other funds holding HAE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VBA

Van Berkom & Associates Montreal, Quebec, Canada $3.08B AUM 12.07% 1-Year Est. Return

Barings's HAE Position: Q3 2016 in Review

Barings sold out of Haemonetics (HAE) in Q3 2016, closing a stake of 13,605 shares — an estimated $394K sold.

Barings first reported a position in HAE in Q1 2014 and held it in 9 quarters. The position peaked at $6.79M in Q3 2014. 180 funds tracked by Wall St. Rank hold HAE as of Q3 2016.

Barings reported no remaining Haemonetics position as of Q3 2016 after selling out during the quarter.
Barings sold 13,605 Haemonetics shares in Q3 2016, an estimated $394K.
Barings first reported a position in Haemonetics in Q1 2014 and held it in 9 quarters.
Barings's Haemonetics position peaked at $6.79M in Q3 2014.
180 funds tracked by Wall St. Rank held Haemonetics as of Q3 2016.

Based on Barings's 13F filing for Q3 2016, filed 14 Nov 2016.